JB Chemicals & Pharmaceuticals Ltd
Fundamental Score
JB Chemicals & Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of JBCHEPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (20.12%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (25.79%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (24.83%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Consistent Growth Track Record (17.16% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (19.62% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (19.78% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (149.19x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹971.49 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 38.14%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
1 factors identified
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for JB Chemicals & Pharmaceuticals Ltd
About JBCHEPHARM
Business Overview
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Company Details
Key Leadership
Corporate Events
JBCHEPHARM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of JB Chemicals & Pharmaceuticals Ltd (JBCHEPHARM)?
As of 29 Jan 2026, 10:39 am IST, JB Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is currently trading at ₹1846.00. The stock has a market capitalization of ₹27.69K (Cr).
Is JBCHEPHARM share price Overvalued or Undervalued?
JBCHEPHARM is currently trading at a P/E ratio of 38.54x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the JB Chemicals & Pharmaceuticals Ltd share price?
Key factors influencing JBCHEPHARM's price include its quarterly earnings growth (Sales Growth: 8.42%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is JB Chemicals & Pharmaceuticals Ltd a good stock for long-term investment?
JB Chemicals & Pharmaceuticals Ltd shows a 5-year Profit Growth of 19.78% and an ROE of 20.12%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing.
How does JB Chemicals & Pharmaceuticals Ltd compare with its industry peers?
JB Chemicals & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare JBCHEPHARM's P/E of 38.54x and ROE of 20.12% against the industry averages to determine its competitive standing.
What is the P/E ratio of JBCHEPHARM and what does it mean?
JBCHEPHARM has a P/E ratio of 38.54x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹39 for every ₹1 of annual earnings.
How is JBCHEPHARM performing according to Bull Run's analysis?
JBCHEPHARM has a Bull Run fundamental score of 60.2/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does JBCHEPHARM belong to?
JBCHEPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting JB Chemicals & Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for JBCHEPHARM?
JBCHEPHARM has an ROE of 20.12%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently JB Chemicals & Pharmaceuticals Ltd generates profits from shareholders' equity.
How is JBCHEPHARM's debt-to-equity ratio and what does it indicate?
JBCHEPHARM has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is JBCHEPHARM's dividend yield and is it a good dividend stock?
JBCHEPHARM offers a dividend yield of 0.88%, which means you receive ₹0.88 annual dividend for every ₹100 invested.
How has JBCHEPHARM grown over the past 5 years?
JBCHEPHARM has achieved 5-year growth rates of: Sales Growth 17.16%, Profit Growth 19.78%, and EPS Growth 19.62%.
What is the promoter holding in JBCHEPHARM and why does it matter?
Promoters hold 47.56% of JBCHEPHARM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is JBCHEPHARM's market capitalization category?
JBCHEPHARM has a market capitalization of ₹27690 crores, placing it in the Large-cap category.
How volatile is JBCHEPHARM stock?
JBCHEPHARM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for JBCHEPHARM?
JBCHEPHARM has a 52-week high of ₹N/A and low of ₹N/A.
What is JBCHEPHARM's operating profit margin trend?
JBCHEPHARM has a 5-year average Operating Profit Margin (OPM) of 24.83%, indicating the company's operational efficiency.
How is JBCHEPHARM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 8.42% and YoY Profit Growth of 19.05%.
What is the institutional holding pattern in JBCHEPHARM?
JBCHEPHARM has FII holding of 15.31% and DII holding of 22.83%. Significant institutional holding often suggests professional confidence in the stock.